Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Mercado, Noe B.; Zahn, Roland; Wegmann, Frank; Loos, Carolin; Chandrashekar, Abishek; Yu, Jingyou; Liu, Jinyan; Peter, Lauren; McMahan, Katherine; Tostanoski, Lisa H.; He, Xuan; Martinez, David R.; Rutten, Lucy; Bos, Rinke; Manen, Danielle; Vellinga, Jort; Custers, Jerome; Langedijk, Johannes P.; Kwaks, Ted; Bakkers, Mark J. G.; Zuijdgeest, David; Huber, Sietske K. Rosendahl; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; Hoffman, Emily; Jacob-Dolan, Catherine; Kirilova, Marinela; Li, Zhenfeng; Lin, Zijin; Mahrokhian, Shant H.; Maxfield, Lori F.; Nampanya, Felix; Nityanandam, Ramya; Nkolola, Joseph P.; Patel, Shivani; Ventura, John D.; Verrington, Kaylee; Wan, Huahua; Pessaint, Laurent; Ry, Alex; Blade, Kelvin; Strasbaugh, Amanda; Cabus, Mehtap; Brown, Renita; Cook, Anthony; Zouantchangadou, Serge; Teow, Elyse; Andersen, Hanne; Lewis, Mark G.; Cai, Yongfei; Chen, Bing; Schmidt, Aaron G.; Reeves, R. Keith; Baric, Ralph S.; Lauffenburger, Douglas A.; Alter, Galit; Stoffels, Paul; Mammen, Mathai; Hoof, Johan; Schuitemaker, Hanneke; Barouch, Dan H.

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H. Tostanoski, Xuan He, David R. Martinez, Lucy Rutten, Rinke Bos, Danielle Manen, Jort Vellinga, Jerome Custers, Johannes P. Langedijk, Ted Kwaks, Mark J. G. Bakkers, David Zuijdgeest, Sietske K. Rosendahl Huber, Caroline Atyeo, Stephanie Fischinger, John S. Burke, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Esther A. Bondzie, Gabriel Dagotto, Makda S. Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova, Zhenfeng Li, Zijin Lin, Shant H. Mahrokhian, Lori F. Maxfield, Felix Nampanya, Ramya Nityanandam, Joseph P. Nkolola, Shivani Patel, John D. Ventura, Kaylee Verrington, Huahua Wan, Laurent Pessaint, Alex Ry, Kelvin Blade, Amanda Strasbaugh, Mehtap Cabus, Renita Brown, Anthony Cook, Serge Zouantchangadou, Elyse Teow, Hanne Andersen, Mark G. Lewis, Yongfei Cai, Bing Chen, Aaron G. Schmidt, R. Keith Reeves, Ralph S. Baric, Douglas A. Lauffenburger, Galit Alter, Paul Stoffels, Mathai Mammen, Johan Hoof, Hanneke Schuitemaker and Dan H. Barouch ()
Additional contact information
Noe B. Mercado: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Roland Zahn: Janssen Vaccines and Prevention BV
Frank Wegmann: Janssen Vaccines and Prevention BV
Carolin Loos: Ragon Institute of MGH, MIT and Harvard
Abishek Chandrashekar: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Jingyou Yu: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Jinyan Liu: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Lauren Peter: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Katherine McMahan: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Lisa H. Tostanoski: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Xuan He: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
David R. Martinez: University of North Carolina at Chapel Hill
Lucy Rutten: Janssen Vaccines and Prevention BV
Rinke Bos: Janssen Vaccines and Prevention BV
Danielle Manen: Janssen Vaccines and Prevention BV
Jort Vellinga: Janssen Vaccines and Prevention BV
Jerome Custers: Janssen Vaccines and Prevention BV
Johannes P. Langedijk: Janssen Vaccines and Prevention BV
Ted Kwaks: Janssen Vaccines and Prevention BV
Mark J. G. Bakkers: Janssen Vaccines and Prevention BV
David Zuijdgeest: Janssen Vaccines and Prevention BV
Sietske K. Rosendahl Huber: Janssen Vaccines and Prevention BV
Caroline Atyeo: Ragon Institute of MGH, MIT and Harvard
Stephanie Fischinger: Ragon Institute of MGH, MIT and Harvard
John S. Burke: Ragon Institute of MGH, MIT and Harvard
Jared Feldman: Ragon Institute of MGH, MIT and Harvard
Blake M. Hauser: Ragon Institute of MGH, MIT and Harvard
Timothy M. Caradonna: Ragon Institute of MGH, MIT and Harvard
Esther A. Bondzie: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Gabriel Dagotto: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Makda S. Gebre: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Emily Hoffman: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Catherine Jacob-Dolan: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Marinela Kirilova: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Zhenfeng Li: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Zijin Lin: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Shant H. Mahrokhian: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Lori F. Maxfield: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Felix Nampanya: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Ramya Nityanandam: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Joseph P. Nkolola: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Shivani Patel: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
John D. Ventura: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Kaylee Verrington: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Huahua Wan: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Laurent Pessaint: Bioqual
Alex Ry: Bioqual
Kelvin Blade: Bioqual
Amanda Strasbaugh: Bioqual
Mehtap Cabus: Bioqual
Renita Brown: Bioqual
Anthony Cook: Bioqual
Serge Zouantchangadou: Bioqual
Elyse Teow: Bioqual
Hanne Andersen: Bioqual
Mark G. Lewis: Bioqual
Yongfei Cai: Children’s Hospital
Bing Chen: Children’s Hospital
Aaron G. Schmidt: Ragon Institute of MGH, MIT and Harvard
R. Keith Reeves: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Ralph S. Baric: University of North Carolina at Chapel Hill
Douglas A. Lauffenburger: Massachusetts Institute of Technology
Galit Alter: Ragon Institute of MGH, MIT and Harvard
Paul Stoffels: Janssen Vaccines and Prevention BV
Mathai Mammen: Janssen Vaccines and Prevention BV
Johan Hoof: Janssen Vaccines and Prevention BV
Hanneke Schuitemaker: Janssen Vaccines and Prevention BV
Dan H. Barouch: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School

Nature, 2020, vol. 586, issue 7830, 583-588

Abstract: Abstract A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1–8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (10)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2607-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:586:y:2020:i:7830:d:10.1038_s41586-020-2607-z

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2607-z

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().